All relevant data are within the paper.

Introduction {#sec005}
============

Image-guided radiotherapy (IGRT) enabled dose escalation to limited volumes and at the same time a reduction of normal tissue complications in external-beam-radiotherapy (EBRT) and stereotactic-body-radiotherapy (SBRT) \[[@pone.0187710.ref001],[@pone.0187710.ref002]\]. The most commonly used technique for pre-treatment imaging is a perpendicularly mounted kilovoltage- (kV) Cone-Beam Computed Tomography (kV-CBCT) \[[@pone.0187710.ref003]--[@pone.0187710.ref005]\] while Megavoltage- (MV) treatment beam has only been used on a limited basis as MV-CBCT \[[@pone.0187710.ref006],[@pone.0187710.ref007]\] due to reduced soft-tissue contrast and reduced quantum efficiency.

An approach increasingly employed to reduce for lung and liver motion is to treat the patient during computer-controlled breath-hold (deep-inspiratory breath-hold, DIBH) \[[@pone.0187710.ref008]\]. While the radiation treatment can now be performed within only a few breath-holds, CBCT image acquisition in repeated breath-hold takes about 3-4min. Although this "start/stop" CBCT imaging approach in combination with multiple breath-holds results in images of excellent image quality \[[@pone.0187710.ref009],[@pone.0187710.ref010]\], it considerably extends the imaging time into the range of flattening filter free treatment delivery \[[@pone.0187710.ref011],[@pone.0187710.ref012]\]. CBCT image acquisition within one single breath-hold (typically 10-20s) would result in high treatment precision with dramatically shortened overall treatment times while significantly increasing patient comfort.

Our novel imaging technique of combined ultrafast kV-MV-CBCT performs image acquisition within one breath-hold of 15s \[[@pone.0187710.ref013],[@pone.0187710.ref014]\]. KV-MV-CBCT is based on the initial step-and-shoot technique introduced by Yin et al. \[[@pone.0187710.ref015]\], but was fully developed by us to be performed dynamically to be completed within 15s, which is a prerequisite for clinical implementation. KV-MV-CBCT is realized by simultaneous image acquisition of 90° kV and 90° MV projections, resulting in 180° image information (+ cone-angle). It can be operated on a clinically commissioned linear accelerator (Elekta Synergy linac) with minimal modifications \[[@pone.0187710.ref014]\]. The development of kV-MV-CBCT is finalized, the workflow is fully automated \[[@pone.0187710.ref016]\] and the image acquisition as well as image registration can be performed in real-time \[[@pone.0187710.ref017]\].

For the implementation of kV-MV-CBCT into clinical routine, imaging dose exposure to the patient has to be investigated and compared to clinically-established techniques. A standard dose value for a kV-MV-CBCT preset has to be defined for future quality assurance and documentation. We performed a comparison of imaging dose applied with kV-CBCT standard presets currently used in clinical routine. First, a lung tumor patient was simulated with an inhomogeneous thorax phantom and the dose exposure was measured at representative positions. Second, the weighted CT dose index was determined with an appropriate CT phantom. Proper ionization chamber calibration was performed for applied kV and MV energies, as well as the relative biological effectiveness was considered.

Methods {#sec006}
=======

KV-MV-CBCT imaging was developed on a clinical 6MV Elekta Synergy linac (Integrity v1.2), equipped with a foldout MV detector (iView GT v3.4) and a perpendicularly mounted kV-CBCT-system (XVI v4.2.2). To compare kV-MV-CBCT with clinically-established techniques, not only the Chest-preset of the Elekta Synergy linac was applied in the phantom dose measurements but also the Chest-preset of the latest available kV-CBCT software version (XVI v5.0.2), installed on a clinical Elekta VersaHD linac (all Elekta AB, Stockholm, Sweden).

Setup of conventional kV-CBCT and kV-MV-CBCT {#sec007}
--------------------------------------------

The imaging dose outputs of the following three imaging techniques were compared in this study (technical setups are summarized in [Table 1](#pone.0187710.t001){ref-type="table"}):

-   **Clinical kV-Chest**~**1**~**-CBCT**

    On the Elekta Synergy linac, the still widely-used XVI version 4.2.2 was installed. The preset routinely applied for lung SBRT was called "kV-Chest~1~" throughout this study.

-   **Clinical kV-Chest**~**2**~**-CBCT**

    The preset "kV-Chest~2~" of the recently introduced XVI version 5.0.2, installed on the Elekta VersaHD linac, differed slightly from the previous preset kV-Chest~1~. A bow-tie filter was applied and the mAs was reduced, as thus was the nominal scan dose (CT dose per volume). Acquisition time remained the same (2min); however, beam interruptions were possible in case of DIBH treatment, extending imaging time to 3-4min.

-   **kV-MV-CBCT**

    The kV-MV-CBCT imaging technique was set up as a simultaneous 90° kV and 90° MV scan, achieved by dedicated in-house developed synchronization hard- and software. Since the MV-panel was initially not developed for continuous imaging, linac-pulsing and panel-readout had to be triggered alternately. Due to limited readout-speed, one MV-projection could only be acquired with every fifth kV-projection, resulting in 19 MV-projections versus 100 kV-projections for a 90° scan (+ cone-angle of 10°).

    Linac-parameters were adjusted with our automated workflow to achieve low-dose output of 4--5 Monitor Units (MU) distributed equally over the 19 MV-projections, depending on wear of magnetron and electron gun. At the time of this study, the output was 4MU for a 100° rotation. Acquired kV- and MV-volumes were reconstructed separately and combined after appropriate grey-scale matching \[[@pone.0187710.ref013],[@pone.0187710.ref014],[@pone.0187710.ref016],[@pone.0187710.ref017]\].

10.1371/journal.pone.0187710.t001

###### Technical setup of applied imaging presets.

![](pone.0187710.t001){#pone.0187710.t001g}

  Preset                           kV-Chest~1~-CBCT                kV-Chest~2~-CBCT                kV-MV-CBCT
  -------------------------------- ------------------------------- ------------------------------- -------------------------
  **Output characteristics**       120kVp                          120kVp                          **kV:** 100kVp
  1mAs (25mA, 40ms) per frame      0.4mAs (20mA, 20ms) per frame   0.1mAs (10mA, 10ms) per frame   
                                                                   **MV:** 6MV linac (4MU)         
  **Number of frames**             650                             660                             **kV:** 100
  **MV:** 19                                                                                       
  **Panel position**               off-centered (M)                off-centered (M)                centered (S)
  **Filter,**                      F0 (empty),                     F1 (bow-tie),                   **kV:** F0 (empty),
  **Collimator (field size)**      M20 (27.67cm x 42.64cm)         M20 (27.67cm x 42.64cm)         S20 (27.67cm x 27.67cm)
                                                                                                   **MV:** 25cm x 25cm
  **Rotation speed**               ½ rpm                           ½ rpm                           1 rpm
  **Acquisition length**           360°                            360°                            90° + cone angle
  (here: 0° to 100°)                                                                               
  **Acquisition time**             2min                            minimum 2min                    15s
  **Nominal dose (uncorrected)**   16mGy                           5mGy                            **kV:** 0.02mGy
  **MV:** 4MU                                                                                      

Determination of beam quality and dose correction factors {#sec008}
---------------------------------------------------------

All absorbed dose measurements were corrected following the AAPM TG protocol 61 \[[@pone.0187710.ref018]\] (kV-energy range) and the IAEA TPS 398 \[[@pone.0187710.ref019]\] (MV-energy range). For both energy ranges, measurements were performed with two differently-calibrated air-filled point-dose flexible cylindrical ionization chambers (Type 31013, 0.3cm^3^ sensitive volumes) and a UNIDOS E Universal dosemeter (all PTW Freiburg GmbH, Freiburg, Germany). The first ionization chamber was calibrated in air kerma for kV-range (50-150kVp), the second ionization chamber was calibrated on absorbed-dose-to-water for 60-Cobalt (MV-range).

The beam qualities and calibration factors for absolute dose measurements in both kV-and MV-energy ranges are determined as follows.

### KV-energy range: Beam quality and correction factors {#sec009}

Following the AAPM TG61 protocol \[[@pone.0187710.ref018]\], kV beam qualities for the applied beam setups were characterized by measuring the half-value-layers (HVL) of aluminum and calibration factors were determined accordingly. Similar adaptation of the AAPM TG61 protocol for kV-CBCT was performed by Song et al. \[[@pone.0187710.ref020]\] in 2008.

[KV beam quality--determination of HVL:]{.ul} A self-made collimator with field size (5.5x5.5)cm^2^ in the isocenter was used to achieve narrow-beam geometry to minimize scatter effects \[[@pone.0187710.ref021]\]. The x-ray source was positioned at 0° and the detector was moved out of the field-of-view (FOV). A measurement stand on top of the treatment couch aligned both the ionization chamber and the varying aluminum absorbers with the center of the FOV (see [Fig 1](#pone.0187710.g001){ref-type="fig"}). The source to surface distance (SSD) was 100cm for the ionization chamber, the aluminum absorbers were positioned at SSD 50cm. The thickness of the attenuator varied from 0.01--10.31mm, the purity of aluminum was 99.9%.

![HVL measurement setup.](pone.0187710.g001){#pone.0187710.g001}

The HVL was measured for all 3 presets (kV-Chest~1~, kV-Chest~2~ and the kV-contribution of kV-MV), with slight modifications such as static gantry position and adapted number of frames. All HVL measurements were normalized. The preset collimators were replaced with the narrow-beam collimator. To determine the HVL, first, the initial dose output I~0~ was measured free in air (take average value from 4 measurements). Thereafter, the thickness of the aluminum absorbers was increased in different step sizes between 0.01mm and 1.06mm, and dose output was measured. The step sizes around the I~0~/2 region were smallest to increase measurement accuracy around the expected HVL value.

In literature, the HVL is usually calculated under ideal conditions of a monoenergetic x-ray beam, following the Lambert-Beer-Law: $$I\left( x \right) = I_{0}e^{- \mu x}$$ $${HVL}_{LB} = \frac{\ln 2}{\mu}\ ,\ {for}\mspace{10mu} I\left( {HVL}_{LB} \right) = \frac{I_{0}}{2},$$ where I(x) is the dose output at depth x in a medium, I~0~ is the initial dose output in air, and μ is the attenuation coefficient of the absorber material.

However, in reality, the x-ray tube produces polyenergetic beams (with peak energy kVp). Inherent beam filtration such as aluminum filters is used for beam hardening, i.e. low-energy x-rays are filtered, which would be absorbed by the patient's body and thus not contribute to imaging but only increase the applied dose to the patient. In 1994, Bjaerngard and Shackford \[[@pone.0187710.ref022]\] analyzed this beam hardening effect. They suggested the following mathematical description of a second-order polynomial in thickness, to analyze the transmission characteristics in terms of varying attenuation coefficient μ and beam-hardening coefficient η: $$I\left( x \right) = I_{0}e^{- \mu x({1 - \eta x})} = I_{0}e^{- \mu x + \mu\eta x^{2}}$$ $${HVL}_{BS} = \frac{\mu - \sqrt{\mu^{2} - 4\mu\eta{\ln 2}}}{2\mu\eta}$$

[KV beam quality--correction factors:]{.ul} After calculating the HVL for each imaging preset following \[[@pone.0187710.ref022]\], the appropriate correction factors could be determined from the look-up-tables provided in \[[@pone.0187710.ref018]\], following the dosimetry formalism for tube voltages between 100-300kV: $$D_{w} = MN_{k}P_{Q,cham}P_{sheath}\ \left\lbrack \left( \frac{\mu_{en}}{\rho} \right)_{air}^{water} \right\rbrack_{water}$$ with *M* = (*M*~*raw*~ − *M*~0~)*P*~*TP*~*P*~*ion*~*P*~*pol*~*P*~*elec*~

The in-phantom formalism converted the air-kerma calibrated ionization chamber reading M \[C\] to absorbed dose-to-water D~w~ \[Gy\]. Further explanations about the correction factors N~k~ (air-kerma calibration), P~Q,cham~ (ionization chamber stem correction), P~sheath~ (ionization chamber waterproofing sheath correction), $\left\lbrack \left( \frac{\mu_{en}}{\rho} \right)_{air}^{water} \right\rbrack_{water}$ (water-to-air ratio of the mass-energy-absorption coefficients averaged over the incident photon spectrum), P~TP~ (temperature-pressure correction), P~ion~ (ion collection efficiency), P~pol~ (polarity correction) and P~elec~ (electrometer correction) can be found in Ma et al. \[[@pone.0187710.ref018]\].

### MV-energy range: Beam quality and correction factors {#sec010}

The determination of MV-energy beam quality differs from the kV beam quality procedure, because the MV beam is already hardened by heavy inherent filtration of target and flattening filter. A convenient method to determine the energy of the MV beam is to measure the percentage depth dose distribution (PDD) and put it in relation to reference data, i.e. 60-Cobalt.

[MV beam quality---determination of quality index Q:]{.ul} Following \[[@pone.0187710.ref019]\], the PDD was measured in a water tank and the beam quality index Q of our clinical 6MV Synergy linac beam was determined. The reference setup was SSD 100cm, field size was 10x10cm^2^ in isocenter, and the PDD was acquired for a depth of 0-30cm in a water tank (IBA blue phantom, IBA Dosimetry, Schwarzenbruck, Germany). The ionization chamber was positioned in the central axis of the beam and corrected for the effective point of measurement.

[MV beam quality--correction factors:]{.ul} From the acquired PDD, the percentage dose values of depths 20cm (M~20~) and 10cm (M~10~) can be selected and the beam quality index can be calculated as follows \[[@pone.0187710.ref019]\]: $$Q = 1.2661\frac{M_{20}}{M_{10}} - 0.0595$$

The absorbed dose-to-water calculation for high energy beams (MV-range) follow the formalism: $$D_{w} = MN_{D,w}k_{Q}$$ with *M* = (*M*~*raw*~ − *M*~0~)*P*~*TP*~*P*~*ion*~*P*~*pol*~*P*~*elec*~

The beam-quality conversion factor k~Q~ converts the calibration factor of the reference energy (Cobalt-60) to the energy of beam quality Q, and can be found in the look-up-table provided in IAEA TRS 398 \[[@pone.0187710.ref019]\]. Further details about the correction factors can be found in literature \[[@pone.0187710.ref019],[@pone.0187710.ref023]\].

Consideration of relative biological effectiveness {#sec011}
--------------------------------------------------

The ICRP-60 and ICRP-103 reports \[[@pone.0187710.ref024],[@pone.0187710.ref025]\] suggest to keep a uniform radiation weighting factor of w~R~ = 1 for all low-LET-radiations such as x-rays, electrons and gamma-rays of all energies. However, several studies discovered an increase in biological effectiveness with decreasing photon energy \[[@pone.0187710.ref026]--[@pone.0187710.ref028]\]. These studies are either based on epidemic data of the Hiroshima and Nagasaki atomic bombs or on *in vitro* radio-biological measures, and show significant differences in biological effectiveness for different energies.

In IGRT, special consideration has to be taken of a potentially increased risk of secondary cancer \[[@pone.0187710.ref029]--[@pone.0187710.ref031]\]. In the review of Nikjoo et al. \[[@pone.0187710.ref028]\], some studies were presented in which the RBE between low- and high-energy photons were compared. For the biological endpoint of neoplastic cell transformation, determined RBE-values range from 2 to 4. Hill et al. \[[@pone.0187710.ref026]\] and Borek et al. \[[@pone.0187710.ref032]\] determined an RBE = 2 for low vs. an RBE = 1 for high photon energies.

In this dosimetry study, a conservative RBE ratio of 2:1 for kV vs. MV biological effectiveness was chosen with regard to secondary cancer risk. MV-dose was then converted to kV-equivalent dose by reducing the MV-dose by one half and denominated Gray-equivalent \[GE\].

Dosimetry phantom setup {#sec012}
-----------------------

Dose measurement comparisons between kV-MV-CBCT and other CBCT-presets were performed on two phantoms. First, dose output was measured in several regions of an inhomogeneous thorax phantom, to simulate patient imaging dose exposure. Second, a CT dose index (CTDI) was determined for kV-MV-CBCT and compared to other imaging techniques.

The dose measurements of kV-MV-CBCT were performed separately for kV- and MV-contribution. Since the beam qualities differed, two differently-calibrated ionization chambers had to be used. This splitting allowed separate evaluation of the dose contributions as well as consideration of RBE to convert MV to kV-equivalent dose, making final absorbed kV-MV dose exposure comparable to the clinical kV-only CBCT-presets.

### Inhomogeneous thorax phantom--patient simulation {#sec013}

The inhomogeneous thorax phantom (model 002LFC, CIRS, Norfolk, VA, USA) consisted of different materials according to the human thorax, i.e. mimicking two lungs and a spinal cord. In our study, a target volume was defined in the lower left lung of the phantom. This tumor-mimicking inlay was to be located in the isocenter ([Fig 1(A)](#pone.0187710.g001){ref-type="fig"}). Dose measurements were performed in representative beam positions of the phantom:

1.  tumor in lower left lung

2.  left lung

3.  right lung

4.  upper periphery

5.  spinal cord

6.  body center

To spare the contralateral lung in analogy to a patient imaging procedure, the kV-MV preset was designed to rotate only on the side of the tumor location, i.e. from gantry position 0--100°.

The MV-contribution of the kV-MV-CBCT was additionally simulated with the Oncentra treatment planning system (Elekta Oncentra Masterplan, Elekta AB, Stockholm, Sweden) for a 4MU per 100° arc.

### CT dose index---QA phantom {#sec014}

Following the quality assurance (QA) protocol of AAPM reports TG179 \[[@pone.0187710.ref004]\] and TG75 \[[@pone.0187710.ref033]\], a standard dose value for regular QA was defined for kV-MV-CBCT. Many CTDI determination and dose comparison studies between different CBCT-presets of Elekta and Varian were published in the last years \[[@pone.0187710.ref034]--[@pone.0187710.ref038]\]. Initially, the CTDI was developed for diagnostic CT, but with the transmission to CBCT and larger field of views, the proper use of ionization chamber had to be reconsidered. Dixon et al. \[[@pone.0187710.ref039]\] suggested to use a small point-dose ionization chamber measuring the central beam of CBCT, instead of the commonly used 10cm long ionization chamber.

In our study, the CTDI measurements were performed in the CT body phantom (T40016, PTW, Freiburg, Germany), made of polymethyl-mathacrylate (PMMA, density ρ = 1.19g/cm^3^), with diameter 32cm and axial length 15cm ([Fig 2(B)](#pone.0187710.g002){ref-type="fig"}). The phantom featured five cavities to sequentially insert the ionization chamber: one center and four peripheral positions (at gantry angle 0°, 90°, 180°, 270°). The dose measurements were again performed with the two differently-calibrated (kV- and MV-energy) point-dose ionization chambers. An additional halved dummy plug was placed into the cavities sequentially together with the ionization chamber at axial midpoint (isocenter) of the phantom to prevent the air gap. The weighted CTDI~w~ was calculated as follows \[[@pone.0187710.ref033]\]: $${CTDI}_{w} = \frac{1}{3}{CTDI}_{c} + \frac{2}{3}{CTDI}_{p}$$ with *CTDI*~*c*~ central dose $${and}\ {CTDI}_{p} = \frac{1}{4}\left( {{CTDI}_{p,0{^\circ}} + {CTDI}_{p,90{^\circ}} + {CTDI}_{p,180{^\circ}} + {CTDI}_{p,270{^\circ}}} \right)$$ peripheral dose (averaged).

![Setup and layout of different measurement positions of (a) inhomogeneous thorax phantom for patient simulation (1: tumor in lower left lung, 2: left lung, 3: right lung, 4: upper periphery, 5: spinal cord, 6: body center), and (b) CT dose body phantom for QA purposes.](pone.0187710.g002){#pone.0187710.g002}

Results {#sec015}
=======

Following the AAPM TG61 protocol (kV-energy) \[[@pone.0187710.ref018]\] for kV-Chest~1~, kV-Chest~2~ and the kV-contribution of kV-MV-CBCT, and the IAEA TRS 398 protocol (MV-energy) \[[@pone.0187710.ref019]\] for the MV-contribution of kV-MV-CBCT, the beam qualities and corresponding calibration factors for dose measurements were determined and applied (see chapter 2.2 and [Table 2](#pone.0187710.t002){ref-type="table"}). [Fig 3(A)](#pone.0187710.g003){ref-type="fig"} shows the HVL measurements and the fit function according to Bjaerngard and Shackford \[[@pone.0187710.ref022]\] (goodness of fit R^2^ = 0.9988--0.9997), the calculated HVL~BS~ matched with our direct measurement results within a 2% maximum difference and was consistent with measurement values found in literature \[[@pone.0187710.ref018],[@pone.0187710.ref020],[@pone.0187710.ref040]\]. The MV PDD is shown in [Fig 3(B)](#pone.0187710.g003){ref-type="fig"}.

![(a) HVL measurement results for all kV-dependent CBCT-presets, (b) PDD for MV beam quality determination, and (c) simulation of 4MU distributed over a 100° gantry arc with the TPS.](pone.0187710.g003){#pone.0187710.g003}

10.1371/journal.pone.0187710.t002

###### Absolute dose correction factors for kV- and MV-energy, based on AAPM TG61 report and IAEA TRS 398, respectively, whereas the values for HVL~BS~ and Q were calculated from the beam quality measurements.
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  kV-energy correction factors                                                              MV-energy correction factors                                          
  ----------------------------------------------------------------------------------------- ------------------------------ ----------- ----------- -------------- ----------------
  *HVL*~*BS*~                                                                               7.01mm Al                      7.63mm Al   5.57mm Al   *Q*            0.6858
  $\left\lbrack \left( \frac{\mu_{en}}{\rho} \right)_{air}^{water} \right\rbrack_{water}$   1.0394                         1.0417      1.0346      *k*~*Q*~       0,9894
  *P*~*Q,cham*~                                                                             1.022                          1.023       1.019       *N*~*D*,*w*~   1.0·10^8^ Gy/C
  *P*~*sheath*~                                                                             1                              1           1                          
  *N*~*k*~                                                                                  8.757·10^7^ Gy/C                                                      

Inhomogeneous thorax phantom--patient simulation {#sec016}
------------------------------------------------

Column 8 in [Table 3](#pone.0187710.t003){ref-type="table"} shows the corrected absolute dose output for the various locations (serially numbered) and imaging methods. The dose measurements of kV-MV-CBCT were performed separately (columns 5 and 7), because the dose responses of kV and MV behaved differently. Furthermore, the separate dose contributions could be distinguished and the different RBE could be considered (column 6), enabling proper dose comparison in kV-range. The final absorbed dose of kV-MV-CBCT in column 8 is the sum of the kV-contribution and the kV-equivalent MV-contribution, the unit is \[GE\].

10.1371/journal.pone.0187710.t003

###### Absorbed dose for different presets in inhomogeneous thorax phantom (column 8), ratio between the imaging methods and reference dose output kV-MV (D/D~ref~) (column 9), comparison of MV-contribution dose output between measured and calculated (TPS) absolute dose by percentage difference (column 3--5), and separate contributions of kV- and RBE-corrected MV absorbed dose to kV-MV-CBCT in columns 6+7 (GE: Gray-equivalent with RBE = 2 for kV-dose contribution).

![](pone.0187710.t003){#pone.0187710.t003g}

  Position                    CBCT    calculated (TPS):   measured:   final absorbed dose   *ratio vs*. *kV-MV*                                   
  --------------------------- ------- ------------------- ----------- --------------------- --------------------- --------------- --------------- ----------
  1: tumor- lower left lung   kV-MV   40.40 mGy           *0*.*35*    40.26 mGy             20.13 mGE             0.38 mGy        **20.51 mGE**   *1*.*00*
  kV-Chest~1~                                                                                                     **31.26 mGy**   *1*.*52*        
  kV-Chest~2~                                                                                                     **9.10 mGy**    *0*.*44*        
  2: upper left lung          kV-MV   44.90 mGy           *0*.*45*    45.10 mGy             22.55 mGE             0.33 mGy        22.88 mGE       *1*.*00*
  kV-Chest~1~                                                                                                     32.00 mGy       *1*.*40*        
  kV-Chest~2~                                                                                                     9.13 mGy        *0*.*40*        
  3: right lung               kV-MV   13.40 mGy           *2*.*84*    13.02 mGy             6.51 mGE              0.09 mGy        **6.60 mGE**    *1*.*00*
  kV-Chest~1~                                                                                                     **22.85 mGy**   *3*.*46*        
  kV-Chest~2~                                                                                                     **5.22 mGy**    *0*.*79*        
  4: upper center             kV-MV   37.30 mGy           *1*.*74*    37.95 mGy             18.98 mGE             0.13 mGy        19.10 mGE       *1*.*00*
  kV-Chest~1~                                                                                                     23.06 mGy       *1*.*21*        
  kV-Chest~2~                                                                                                     6.21 mGy        *0*.*33*        
  5: spinal cord              kV-MV   30.00 mGy           *0*.*60*    29.82 mGy             14.91 mGE             0.20 mGy        15.12 mGE       *1*.*00*
  kV-Chest~1~                                                                                                     16.45 mGy       *1*.*09*        
  kV-Chest~2~                                                                                                     4.62 mGy        *0*.*31*        
  6: body center              kV-MV   34.30 mGy           *1*.*55*    34.83 mGy             17.41 mGE             0.16 mGy        17.57 mGE       *1*.*00*
  kV-Chest~1~                                                                                                     21.54 mGy       *1*.*23*        
  kV-Chest~2~                                                                                                     5.96 mGy        *0*.*34*        

### Comparison of MV dose measured vs. calculated (TPS) {#sec017}

To demonstrate asymmetric dose distribution of kV-MV-CBCT, the MV-contribution was simulated in the Oncentra TPS. The axial dose distribution of 4MU equally distributed over 100° is shown in [Fig 3(C)](#pone.0187710.g003){ref-type="fig"}, the calculated MV dose outputs are listed in column 3 of [Table 3](#pone.0187710.t003){ref-type="table"}. In this comparison the RBE was not considered, i.e. the originally measured absorbed dose was shown. The percentage difference between measured and calculated MV dose values with a maximum difference of 2.8% underlined a proper MV dose output also in low-dose mode (column 4 of [Table 3](#pone.0187710.t003){ref-type="table"}).

### Dose comparison of kV-MV imaging vs. conventional CBCT {#sec018}

Column 9 of [Table 3](#pone.0187710.t003){ref-type="table"} gives an overview of the ratios between kV-Chest~1~ respective kV-Chest~2~ versus kV-MV-CBCT. Among each other, the two clinical presets kV-Chest~1~ and kV-Chest~2~ differed mainly in the applied nominal tube current (mA) and pulse duration (ms), see [Table 1](#pone.0187710.t001){ref-type="table"}. Furthermore, the bow-tie filter in kV-Chest~2~-CBCT also reduced imaging dose \[[@pone.0187710.ref041]\]. KV-Chest~1~ resulted in an absolute dose of 31.26mGy in the tumor and 22.85mGy in the contralateral lung. For kV-Chest~2~, these dose values were reduced by a factor of 3--4, resulting in 9.10mGy for the tumor region and 5.22mGy for the organ at risk. Dose output was slightly inhomogeneous distributed around the phantom due to the fact that the phantom was positioned off-centered. The smallest dose was detected in the spinal cord.

KV-MV-CBCT dose outputs lay in between the dose outputs of both kV-presets. Maximum dose of kV-MV-CBCT was 22.88mGE at the left lung position. Minimum dose of 6.60mGE was exposed to the contralateral lung. This was due to asymmetric dose distribution; organs at risk could be spared. At the tumor position, dose output of the kV-MV approach was 20.51mGE, i.e. it was 34% smaller than kV-Chest~1~ and 2.25 times higher than kV-Chest~2~. The largest difference of 3.3 times the dose output of the kV-Chest~2~-CBCT appeared at the position of the spinal cord. Compared to the kV-Chest~1~-CBCT, however, kV-MV dose output was still 8% lower.

CTDI quality assurance {#sec019}
----------------------

The CTDI~w~ was calculated following [Eq 8](#pone.0187710.e009){ref-type="disp-formula"}. The resulting dose values for each of the five measurement points as well as the final weighted CTDI are listed in [Table 4](#pone.0187710.t004){ref-type="table"}. The MV-contribution of the kV-MV-CBCT dose measurement results were converted to kV-equivalent dose by taking half of the MV dose value. This kV-equivalent MV dose was added to the kV-contribution, resulting in the final absorbed kV-MV-CBCT dose output.

10.1371/journal.pone.0187710.t004

###### Determination of weighted CTDI for different CBCT-presets (GE: Gray-equivalent with RBE = 2 for kV-dose contribution) (columns 2, 3 and 5) and ratio between the imaging methods and reference dose output kV-MV (D/D~ref~) (columns 4 and 6).
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  Position                 kV-MV-CBCT      kV-Chest~1~-CBCT   *ratio vs*. *kV-MV*   kV-Chest~2~-CBCT   *ratio vs*. *kV-MV*
  ------------------------ --------------- ------------------ --------------------- ------------------ ---------------------
  **CTDI**~**c**~          14.70 mGE       9.68 mGy           *0*.*66*              3.42 mGy           *0*.*23*
  **CTDI**~**p,\ 0°**~     19.83 mGE       20.52 mGy          *1*.*03*              6.41 mGy           *0*.*32*
  **CTDI**~**p,\ 90°**~    16.72 mGE       20.24 mGy          *1*.*21*              6.00 mGy           *0*.*36*
  **CTDI**~**p,\ 180°**~   5.66 mGE        20.61 mGy          *3*.*64*              5.53 mGy           *0*.*98*
  **CTDI**~**p,\ 270°**~   5.74 mGE        22.27 mGy          *3*.*88*              6.74 mGy           *1*.*17*
  **CTDI**~**w**~          **11.99 mGE**   **17.16 mGy**      *1*.*43*              **5.25 mGy**       *0*.*44*

### Dose comparison of kV-MV imaging vs. conventional CBCT {#sec020}

Among each other, the clinical presets kV-Chest~1~ and kV-Chest~2~ differed in nominal dose output about a factor of 3.2, due to different tube current per pulse duration (mAs) and different filters (see [Table 1](#pone.0187710.t001){ref-type="table"}), which transmits to the different dose output. This difference is also seen in the comparison of CTDI~w~: the measured weighted CT dose index for kV-Chest~1~ is 17.16mGy, and 5.25mGy for kV-Chest~2~. The kV-MV weighted CT dose index was in between both clinical presets, with CTDI~w~ = 11.99mGE.

Discussion {#sec021}
==========

While currently standard clinical kV-CBCT image acquisition for lung tumor position verification takes about 3-4min in repeated breath-hold, our in-house developed and recently fully established automatic ultrafast combined kV-MV-CBCT method enables imaging within only one single breath-hold of 15s \[[@pone.0187710.ref016],[@pone.0187710.ref017]\], providing promising approach for DIBH-patients suffering from lung cancer \[[@pone.0187710.ref008]\].

For clinical implementation of a novel imaging technique, feasibility has to be evaluated regarding fulfillment of sufficient image quality for registration within 1mm and small dose exposure compared to prescribed dose. Excellent registration accuracy of combined kV-MV-CBCT was recently reported \[[@pone.0187710.ref017]\]. A remaining issue, however, is the dose exposure to the patient. The MV-contribution of kV-MV-CBCT could be a critical dosimetric issue and therefore merits comparison with standard kV-CBCT.

The kV-MV dose output in this study was composed as a sum of the kV-contribution, and the MV-contribution converted into kV-equivalent dose by considering changes in RBE between both kV- and MV-energies. Following recommendations in literature \[[@pone.0187710.ref026],[@pone.0187710.ref032]\], a conservative RBE of 2 vs. 1 was chosen for kV vs. MV dose.

A hallmark of kV-MV-CBCT is its asymmetric dose distribution, due to the limited gantry angle rotation of 90°. The maximum dose was in the left lung where the tumor was located and the kV- and MV-contributions overlapped. Healthy tissue such as the contralateral lung could therefore be spared; kV-MV dose in the healthy right lung was thus 2/3 lower than the clinical preset kV-Chest~1~. Compared to latest available kV-Chest~2~, the kV-MV-CBCT dose is up to 3.3 times higher, whereas the dose value in the contralateral lung was almost the same, due to homogeneous distribution of kV-Chest~2~.

In 2015, Alaei and Spezi \[[@pone.0187710.ref042]\] published a detailed review of more than 500 publications on both kV and MV-CBCT imaging dose. Most of the presented studies performed dose measurements with the clinical kV-CBCT presets provided by the manufacturers. They either measured CTDI \[[@pone.0187710.ref020],[@pone.0187710.ref034],[@pone.0187710.ref043]\], or tried to estimate imaging dose to the patient by phantom measurements \[[@pone.0187710.ref044],[@pone.0187710.ref045]\] or Monte Carlo simulations \[[@pone.0187710.ref037],[@pone.0187710.ref046]\]. However, previous studies did not consider the different RBE of kV imaging \[[@pone.0187710.ref043]\], neither in their dose calculations, nor in their risk analysis. Not only physical dose but also its biological relevance should therefore be considered in any comparison. The trade-off between benefits of frequent imaging and its downside, additional dose to non-target tissues, is currently discussed \[[@pone.0187710.ref043],[@pone.0187710.ref047],[@pone.0187710.ref048]\]. All in \[[@pone.0187710.ref042]\] reviewed fractional dose values vary strongly due to different methods and phantoms, but common kV dose values are reported to be between 10-50mGy for internal organs and up to 70mGy for skin. For linac-based MV-CBCT, doses of 100-150mGy per fraction are typical if the 6MV therapeutic beam is used, and is therefore usually accounted for in treatment planning \[[@pone.0187710.ref006],[@pone.0187710.ref007]\]. The MV-CT installed on a Hi-Art Tomotherapy unit however uses 3.5MV for imaging and results in the range of 20mGy for CTDI~w~ \[[@pone.0187710.ref049]\]. All these values however do not consider different RBE for kV- and MV-energy range. In 2015, Liu et al. \[[@pone.0187710.ref050]\] published a theoretical approach to combine kV- and MV-CBCT imaging focusing on image quality only with their fractional imaging doses of 0.5-2Gy, making a clinical implementation impossible at this stage of research. The non-RBE corrected dose output of our novel kV-MV-CBCT implementation, however, already produced an acceptable range from 13.11--45.43mGy in inhomogeneous thorax phantom measurements. In case of different wear of magnetron and electron gun, an MV output of 5MU would lead to a dose output between \~16-57mGy. In our approach, exceeding 5MU per 90° arc (+ cone-angle) would not be possible because of hard-coded interlock in our automated kV-MV workflow \[[@pone.0187710.ref014],[@pone.0187710.ref016]\].

Therefore it can be concluded that not only the dose output results of our clinical CBCT-presets kV-Chest~1~ and kV-Chest~2~ are in close agreement with the above-mentioned literature \[[@pone.0187710.ref042]\], but also kV-MV-CBCT. The MV-contribution is relatively small compared to MV-CBCT dose outputs in literature \[[@pone.0187710.ref006],[@pone.0187710.ref042]\] or standard EPID verifications (\~4MU) and does not have to be considered in treatment planning, because we triggered the MV-output to low dose and our imaging time is reduced to only 15s \[[@pone.0187710.ref014],[@pone.0187710.ref016]\]. Furthermore, kV-MV could reduce dose exposure to sensitive patient skin due to the MV-build-up effect.

Eventually, the most important aspect of the dosimetric properties of kV-MV-CBCT is that the determined imaging doses of approximately 22mGE/ 45mGy remain negligible compared to the prescribed dose, particularly for SBRT \[[@pone.0187710.ref043]\].

Conclusions {#sec022}
===========

This comparison study demonstrated that the dosimetric properties of kV-MV-CBCT were in agreement with common clinically established imaging techniques, whereas biologically effective exposure to healthy tissue was reduced. Together with the previously published report on registration accuracy with kV-MV-CBCT \[[@pone.0187710.ref017]\], this dosimetric study demonstrates that kV-MV-CBCT fulfills all necessary requirements for imminent clinical implementation.
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